The Duchenne muscular dystrophy clinical trial analysis report delivers important insights into ongoing research of 75+ ...
The father of a boy with a muscle-wasting disease has said he is "incredibly happy" that his son will now get access to a new ...
Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen res ...
Families, friends, and supporters from coast to coast to coast are walking, running, and rolling this May, in support of the ...
Duchenne muscular dystrophy has several approved drugs, including a gene therapy that provides children who have the rare, inherited muscle-wasting disease the option of a one-time treatment. But each ...
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...
May 7 (Reuters) - Entrada Therapeutics' drug for children with Duchenne muscular dystrophy fell well short of analyst expectations in an early-to-mid stage trial, sending its shares down more than 50% ...
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...
CureDuchenne, a global leader in funding and advancing research for Duchenne muscular dystrophy, today announced a second investment into Tevard Biosciences to support the advancement of the company's ...
Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...
Regenxbio (RGNX) stock drops after the company posted late-stage trial data for RGX-202, a gene therapy targeting Duchenne ...
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results